Generation Bio pivots to ctLNP siRNA for autoimmune diseases; CFO, CSO exit; cuts 20% staff

Generation Bio Co.

New focus on ctLNP-delivered siRNA for T cell-driven autoimmune diseases; first IND expected 2H 2026.
CFO Matthew Norkunas departs Jan 10; Kevin Conway appointed CFO with $420K salary and 290,960 option grant.
CSO Matthew Stanton departs; Phillip Samayoa appointed CSO with $510K salary; Stanton to consult through mid-2025.
Workforce reduced ~20%; severance costs estimated $1-2M; cash runway into 2H 2027.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Matthew Norkunas

Chief Financial Officer

Generation Bio Co.

Effective: 2025-01-10
Successor: Kevin Conway
Filed: January 6, 2025, 6:59 PM ET

On January 6, 2025, Generation Bio Co. (the “Company”) and Matthew Norkunas, MD, MBA agreed that they will enter into a separation agreement (the “Norkunas Separation Agreement”) for Dr. Norkunas’s departure as the Company’s Chief Financial Officer, effective as of January 10, 2025 (the “Effective Date”).

Departed

Matthew Stanton

Chief Scientific Officer

Generation Bio Co.

Effective: 2025-01-10
Filed: January 6, 2025, 6:59 PM ET

On January 6, 2025, the Company and Matthew Stanton, Ph.D. agreed that they will enter into a separation agreement (the “Stanton Separation Agreement”) for Dr. Stanton’s departure as the Company’s Chief Scientific Officer, effective as of the Effective Date.

Appointed

Kevin Conway

Chief Financial Officer

Generation Bio Co.

Effective: 2025-01-10
Filed: January 6, 2025, 6:59 PM ET

On January 6, 2025, the Board of Directors (the “Board”) of the Company elected Kevin Conway to serve as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Norkunas departed as Chief Financial Officer at Generation Bio Co..

Action: departure
Role: Chief Financial Officer

Exact text from the filing

On January 6, 2025, Generation Bio Co. (the “Company”) and Matthew Norkunas, MD, MBA agreed that they will enter into a separation agreement (the “Norkunas Separation Agreement”) for Dr. Norkunas’s departure as the Company’s Chief Financial Officer, effective as of January 10, 2025 (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Stanton departed as Chief Scientific Officer at Generation Bio Co..

Action: departure
Role: Chief Scientific Officer

Exact text from the filing

On January 6, 2025, the Company and Matthew Stanton, Ph.D. agreed that they will enter into a separation agreement (the “Stanton Separation Agreement”) for Dr. Stanton’s departure as the Company’s Chief Scientific Officer, effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Conway was elected as Chief Financial Officer at Generation Bio Co..

Action: elected
Role: Chief Financial Officer

Exact text from the filing

On January 6, 2025, the Board of Directors (the “Board”) of the Company elected Kevin Conway to serve as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the Effective Date.

View on SEC.gov

Source: SEC EDGAR

accession 0001558370-25-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.